Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis

Clinical Microbiology and Infection

Volumn 14, Issue 8, 2008, Pages 766-777

  Lemaire, S ^a   Kosowska Shick, K ^b   Julian, K ^b   Tulkens, P M ^a   Van Bambeke, F ^a   Appelbaum, P C ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Daptomycin; Fusidic acid; Linezolid; Macrophages; Oritavancin; Quinupristin dalfopristin; Resistance; Rifampicin; S. aureus; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; CARBON 14; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; METICILLIN; MOXIFLOXACIN; N ACETYLGLUCOSAMINE; ORITAVANCIN; OXACILLIN; OXYTETRACYCLINE; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLYSIS; BACTEREMIA; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; CASE REPORT; CELL LABELING; COLONY FORMING UNIT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BINDING; HUMAN; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION;

STAPHYLOCOCCUS AUREUS;

EID: 48449084148     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02035.x     Document Type: Article

References (53)

1. Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 2003; 111: 1265-1273.
2. Appelbaum PC. MRSA - the tip of the iceberg. Clin Microbiol Infect 2006; 12 (suppl 2): 3-10.
3. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12 (suppl 1): 16-23.
4. Maor Y, Rahav G, Belausov N, Ben David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007; 45: 1511-1514.
5. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007; 30: 398-408.
6. Reipert A, Ehlert K, Kast T, Bierbaum G. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob Agents Chemother 2003; 47: 568-576.
7. Cui L, Iwamoto A, Lian JQ et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 428-438.
8. Boyle-Vavra S, Challapalli M, Daum RS. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob Agents Chemother 2003; 47: 2036-2039.
9. Plouin-Gaudon I, Clement S, Huggler E et al. Intracellular residency is frequently associated with recurrent Staphylococcus aureus rhinosinusitis. Rhinology 2006; 44: 249-254.
10. Clement S, Vaudaux P, Francois P et al. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J Infect Dis 2005; 192: 1023-1028.
11. Ellington JK, Harris M, Webb L et al. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J Bone Joint Surg Br 2003; 85: 918-921.
12. Sinha B, Herrmann M. Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus. Thromb Haemost 2005; 94: 266-277.
13. Mempel M, Schnopp C, Hojka M et al. Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br J Dermatol 2002; 146: 943-951.
14. Krut O, Sommer H, Kronke M. Antibiotic-induced persistence of cytotoxic Staphylococcus aureus in non-phagocytic cells. J Antimicrob Chemother 2004; 53: 167-173.
15. Bhateja P, Purnapatre K, Dube S, Fatma T, Rattan A. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains. Int J Antimicrob Agents 2006; 27: 201-211.
16. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179: 2557-2566.
17. Sieradzki K, Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 2003; 185: 7103-7110.
18. Julian K, Kosowska-Shick K, Whitener C et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 2007; 51: 3445-3448.
19. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Activity of three [beta]-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother 2005; 55: 897-904.
20. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841-851.
21. Shopsin B, Mathema B, Alcabes P et al. Prevalence of agr specificity groups among Staphylococcus aureus strains colonizing children and their guardians. J Clin Microbiol 2003; 41: 456-459.
22. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 5026-5033.
23. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob Agents Chemother 2007; 51: 1627-1632.
24. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and Madin-Darby canine kidney cells. Antimicrob Agents Chemother 2007; 51: 2748-2757.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
26. Cheung HY, Vitkovic L, Freese E. Rates of peptidoglycan turnover and cell growth of Bacillus subtilis are correlated. J Bacteriol 1983; 156: 1099-1106.
27. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 2003; 47: 2283-2292.
28. Scorneaux B, Ouadrhiri Y, Anzalone G, Tulkens PM. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob Agents Chemother 1996; 40: 1225-1230.
29. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210-4219.
30. Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP. 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992; 30 (suppl A): 67-75.
31. Clarebout G, Nativelle E, Bozdogan B, Villers C, Leclercq R. Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLS(B) phenotype of resistance according to the erm gene type. Int J Antimicrob Agents 2004; 24: 444-449.
32. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group.II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-1705.
33. Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 2005; 55: 511-517.
34. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 1177-1184.
35. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
36. Pereira PM, Filipe SR, Tomasz A, Pinho MG. Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3627-3633.
37. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Staphylococcus aureus accessory gene regulator (agr) group II: Is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187: 929-938.
38. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 (suppl 1): S13-S24.
39. Marty FM, Yeh WW, Wennersten CB et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44: 595-597.
40. Kaatz GW, Lundstrom TS, Seo SM. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006; 28: 280-287.
41. Jones T, Yeaman MR, Sakoulas G et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52: 269-278.
42. Lowy FD. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000; 8: 341-343.
43. Baltch AL, Ritz WJ, Bopp LH, Michelsen PB, Smith RP. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 1559-1562.
44. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999; 12 (suppl 2): S45-S58.
45. von Eiff C. Staphylococcus aureus small colony variants: A challenge to microbiologists and clinicians. Int J Antimicrob Agents 2008; 31: 507-510.
46. Van Bambeke F, Mingeot-Leclercq MP, Struelens MJ, Tulkens PM. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol Sci 2008; 25: 124-134.
47. Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides. Drugs 1996; 51 (suppl 1): 20-30.
48. Desnottes JF, Diallo N. Cellular uptake and intracellular bactericidal activity of RP. 59500 in murine macrophages. J Antimicrob Chemother 1992; 30 (suppl A): 107-115.
49. Van Bambeke F, Carryn S, Seral C et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004; 48: 2853-2860.
50. Tulkens P, Trouet A. The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem Pharmacol 1978; 27: 415-424.
51. Maurin M, Raoult D. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother 2001; 45: 2977-2986.
52. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-1215.
53. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline. Wayne, PA: NCCLS, 1998.